3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
3
Neoplasms
3
Lymphoma
3
Leukemia
3
Infections
3
Paraneoplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Bacterial Infections
1
Agammaglobulinemia
1
Interventions
Cyclophosphamide
29
fludarabine
19
Rituximab
15
fludarabine phosphate
12
Specimen Handling
8
obinutuzumab
7
Immunotherapy, Adoptive
7
Lenalidomide
6
Etoposide
6
pirtobrutinib
5
ibrutinib
5
glofitamab
5
axicabtagene ciloleucel
5
Whole-Body Irradiation
5
Mycophenolic Acid
5
venetoclax
4
polatuzumab vedotin
4
Prednisone
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
Doxorubicin
4
Blood Component Removal
4
Biopsy
4
pembrolizumab
3
daratumumab
3
X-Rays
3
Vincristine
3
Stem Cell Transplantation
3
Interleukin-2
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma, Non-Hodgkin
×
gamma-Globulins
×
Clear all
NCT05645107
2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3
Recruiting
386 enrolled